Key Takeaways
- 60% of eyes extended treatment intervals beyond 8 weeks after switching to aflibercept 8 mg
- Mean central retinal thickness decreased by 16 μm, while visual acuity remained stable
- Mean treatment interval reached 11.3 weeks overall and 13.3 weeks in those who achieved extension
Switching to aflibercept 8 mg may allow longer treatment intervals while maintaining anatomical outcomes in patients with neovascular age-related macular degeneration (nARMD) who previously had a suboptimal response to anti-VEGF therapy, according to a poster presented at ARVO 2026 Annual Meeting.
In this case-control study, 126 eyes from 123 patients on a treat-and-extend regimen who had been unable to extend beyond 8-week intervals with prior therapy were switched to aflibercept 8 mg. Patients had previously received either aflibercept 2 mg or faricimab and were followed for at least 12 months after the switch. Treatment intervals were adjusted based on optical coherence tomography findings, with extensions granted in the absence of disease activity.
At 12 months, 60% of eyes extended treatment beyond 8 weeks. In these eyes, the average interval was 13.3 weeks, compared with 11.3 weeks across all patients at the final visit.
Central retinal thickness decreased by a mean of 16 μm (P < 0.001), while best corrected visual acuity showed a minimal, non-significant change (P = 0.41).
Reference
Papadakis G, et al. 12-month real-world outcomes of switching to aflibercept 8 mg in suboptimal responders with neovascular age-related macular degeneration. Poster presented at: ARVO 2026 Annual Meeting; May 3-7, 2026; Denver, CO.
Related Content
